Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies
Rodridguez Rodriguez, L.; Hall, J.; Cardozo-Ojeda, F.; Lynch, R. M.; Perelson, A. S.; Schiffer, J. T.; Reeves, D. B.
Show abstract
Broadly neutralizing antibodies (bnAbs) are a promising intervention for HIV prevention, therapy, and cure. bnAb optimization requires precise quantification of in vivo functions, many of which cannot be directly measured in humans. We therefore performed a mathematical modeling meta-analysis which integrated four clinical trials and reproduced serial bnAb concentrations, viral loads, and bnAb sensitivities (IC50) in 43 viremic trial participants who received an infusion of VRC01, VRC01LS, VRC07-523LS, 3BNC117 or 10-1074. We compared >300 mathematical models for their ability to recapitulate multi-strain HIV dynamics following bnAb infusion. For each bnAb, our best model identified a scaling factor of 36-462 to project in vivo activity from in vitro IC50, quantified Fc-mediated infected cell killing in humans over time, and projected the timing of bnAb-resistant strain emergence. Using this holistic profile, VRC07-523-LS was generally optimal.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains 96%
- Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted / founder sensitivity to broadly neutralizing antibodies 96%
- Probabilities of HIV-1 bNAb development in healthy and chronically infected individuals 95%
Similar papers in this journal
- Principles of dengue virus evolvability derived from genotype-fitness maps in human and mosquito cells 96%
- Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies 96%
- Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1 95%
Similar papers in this journal
Similar papers in this journal
- Mechanism for evolution of diverse autologous antibodies upon broadly neutralizing antibody therapy of people with HIV 97%
- Transient glycan-shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques 96%
- Several cell-intrinsic effectors drive type I interferon-mediated restriction of HIV-1 in primary CD4+ T cells 96%
Similar papers in this journal
- Deep mutational scanning reveals functional constraints and antigenic variability of Lassa virus glycoprotein complex 96%
- HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy 95%
- HIV rapidly targets a diverse pool of CD4+ T cells to establish productive and latent infections 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.